Transgenomic (TBIO) Misses Q3 EPS by 7c

Transgenomic (NASDAQ: TBIO) reported Q3 EPS of ($0.37), $0.07 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $7.4 million.

For earnings history and earnings-related data on Transgenomic (TBIO) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Largo restructures $82.2M in debt, extending maturity to 2030
• Evolution Petroleum closes $16M Midland Basin royalty acquisition